Ani Pharmaceuticals SVP & CFO Stephen Carey sells $207,480 in stock

Stephen P. Carey, the SVP & CFO of ANI Pharmaceuticals Inc., sold 2,850 shares of the company's common stock on August 31, 2026, earning $207,480. The trades were executed via a pre-approved plan on March 6, 2026, and resulted in Carey holding 171,843 shares of ANI Pharmaceuticals at the time of the sale. ANI Pharmaceuticals also reported robust second-quarter 2026 earnings, beating analyst projections with adjusted earnings of $2.21 per share versus an expected $2.03.

Revenue reached a record $266 million, surpassing forecasts of $262.14 million. However, the company adjusted its full-year guidance for Cortrophin due to weak first-half performance, reducing expectations by $20 million to $25 million. Analysts maintained a Buy rating on the stock, with price targets adjusted slightly downward from $124 to $119 by Guggenheim and from $91 to $90 by Canaccord Genuity, citing Cortrophin underperformance as a concern.

Despite the positive quarter results, analysts emphasized the need to monitor ANI Pharmaceuticals' future performance, particularly regarding Cortrophin sales.